In addition to antigens and functional proteins (e.g., enzymes) from viruses, bacteria, or cancer, the mRNA platform can be used to produce monoclonal, bispecific, and VHH antibodies. There are several mRNA-encoded antibody candidates being developed for different uses in preclinical or clinical studies.
Defense against virus by mRNA-encoded antibodies
The mRNAs are available for delivery of specific monoclonal, bispecific and VHH antibodies against viruses that include mRNA-HB27-LNP, VEEV-rep-CB6 for SARS-CoV-2, mRNA-VRC01-LNP for HIV-1, mRNA-RiboBiFEs for influenza virus, ZIKV-117 repRNA for Zika virus, CHKV-24 mRNA for chikungunya virus and mRNA-G12-LNP in Hepatitis B virus (HBV), and anti-RSV VHH mRNA.
Tumor treatment by mRNAs encoding antibodies
Monoclonal and bispecific antibodies are utilized extensively in the treatment of cancer, including PD-1/PD-L1 antibodies, epidermal growth factor receptor (EGFR) antibodies, and HER-2 antibodies, etc.
mRNA-encoding antibodies can be developed to replace recombinant antibodies. Many researchers have used IVT mRNAs to provide full-length antibodies against PD-1, CD20, CD3 (RiboMAbs), CLDN18.2 (RiboMab01).
Yaohai Bio-Pharma Offers One-Stop Solution for RNA
Custom Deliverables
|
Grade
|
Deliverables
|
Specification
|
Applications
|
|
non-GMP
|
Drug Substance, mRNA
|
0.1~10 mg (mRNA)
|
Preclinical research such as cell transfection, Analytical method development, Pre-stability studies, Formulation development
|
|
Drug Product, LNP-mRNA
|
|
GMP, Sterility
|
Drug Substance, mRNA
|
10 mg~70 g
|
Investigational new drug (IND), Clinical trial authorisation (CTA), Clinical trial supply, Biologic license application (BLA), Commercial supply
|
|
Drug Product, LNP-mRNA
|
5000 vials or pre-filled syringes/ cartridges
|
EN
AR
HR
CS
DA
NL
FI
FR
DE
EL
IT
JA
KO
NO
PL
PT
RO
RU
ES
SV
IW
ID
LV
LT
SR
SK
SL
UK
VI
ET
HU
TH
TR
FA
AF
MS
BE
MK
UR
BN
